Esperion Therapeutics, Inc.
ESPRInactive ticker- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001434868
No open-market purchases or sales by Esperion Therapeutics, Inc. insiders were filed in the last 90 days; 191 institutions reported holding it in 13F filings for Q2 2026, worth $646.8M in total; Soros Fund Management is the only superinvestor holding it.
This ticker is no longer on the SEC's list of tickers: the company may have been delisted, or the ticker has changed.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 191
- Q2 2026, −15 vs. previous quarter
- 13F value
- $646.8M
- Reported value at the end of Q2 2026
- Superinvestors holding
- 1
- At the end of Q2 2026
Superinvestors holding ESPR, Q2 2026
1 superinvestor reports holding Esperion Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Soros Fund Management
George Soros
<0.1%
Esperion Therapeutics, Inc.'s share of the portfolio
- Shares
- 757,358
- Value
- $2.39M
Latest insider trades
Open-market purchases and sales by Esperion Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 18, 2026 (view filing) | Jun 17 | 1 day | Looker BenjaminChief Legal Officer | SSale | −11.8K | $3.16 | −$37.4K | −1.7%667.5K after | |
| Jun 18, 2026 (view filing) | Jun 17 | 1 day | Koenig Sheldon L.President and CEO | SSale | −53.6K | $3.16 | −$169.3K | −2.5%2.12M after | |
| Jun 18, 2026 (view filing) | Jun 17 | 1 day | Halladay BenjaminChief Financial Officer | SSale | −10.8K | $3.16 | −$34.0K | −1.5%702.8K after | |
| Mar 18, 2026 (view filing) | Mar 17 | 1 day | Looker BenjaminChief Legal Officer | SSale | −5.71K | $2.70 | −$15.4K | −0.8%679.3K after | |
| Mar 18, 2026 (view filing) | Mar 17 | 1 day | Koenig Sheldon L.President and CEO | SSale | −25.6K | $2.72 | −$69.6K | −1.2%2.17M after | |
| Mar 18, 2026 (view filing) | Mar 17 | 1 day | Halladay BenjaminChief Financial Officer | SSale | −6.42K | $2.71 | −$17.4K | −0.9%713.6K after | |
| Jan 21, 2026 (view filing) | Jan 20 | 1 day | Looker BenjaminGeneral Counsel | SSale | −1.69K | $2.88 | −$4.86K | −0.4%384.2K after | |
| Dec 18, 2025 (view filing) | Dec 17 | 1 day | Koenig Sheldon L.President and CEO | SSale | −48.2K | $3.67 | −$177.1K | −3.2%1.47M after | |
| Dec 18, 2025 (view filing) | Dec 17 | 1 day | Halladay BenjaminChief Financial Officer | SSale | −7.34K | $3.67 | −$26.9K | −1.5%467.5K after | |
| Dec 18, 2025 (view filing) | Dec 17 | 1 day | Looker BenjaminGeneral Counsel | SSale | −6.52K | $3.67 | −$23.9K | −1.7%385.9K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Esperion Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Glazer Capital, LLC | 22,416,339 | $70.8M | 1.75% | +22,416,339 | New |
| BlackRock, Inc. | 22,128,021 | $69.9M | 0.00% | +4,275,594+23.9% | Added |
| Vanguard Capital Management LLC | 11,427,437 | $36.1M | 0.00% | +993,677+9.5% | Added |
| Trium Capital LLP | 11,158,150 | $35.3M | 22.22% | +11,158,150 | New |
| Goldman Sachs Group Inc | 10,380,646 | $32.8M | 0.00% | +7,970,192+330.7% | Added |
| State Street Corp | 7,276,249 | $23.0M | 0.00% | +220,455+3.1% | Added |
| Two Sigma Investments, LP | 7,126,739 | $22.5M | 0.02% | −2,332,040−24.7% | Reduced |
| Geode Capital Management, LLC | 6,629,966 | $21.0M | 0.00% | +674,227+11.3% | Added |
| CNH Partners LLC | 6,046,463 | $19.1M | 0.27% | +6,046,463 | New |
| Oddo BHF Asset Management SAS | 5,000,000 | $15.8M | 0.73% | +5,000,000 | New |